||| Menü 
Startseite
Firmenveranstaltungen, Neuemissionen

10/11
09/11
08/11
07/09
08/09
09/09
10/09
11/09
12/09
01/10
02/10
03/10
Geschäftsberichte, Werbung, Earnings, Marketing, Verordnungen

10/11
09/11
03/09
04/09
05/09
06/09
08/09
09/09
10/09
11/09
12/09
01/10
02/10
Fusionen, Übernahmen

11/11
12/08
01/09
02/09
03/09
04/09
05/09
06/09
07/09
08/09
09/09
10/09
11/09
Personal, Belegschaft, Meldungen zu Produkten

06/08
07/08
08/08
09/08
10/08
11/08
12/08
01/09
02/09
03/09
04/09
05/09
06/09
07/09
08/09

Datenschutz
Impressum
Bankleitzahlen - online.de


Novartis appoints Elizabeth Barrett as Oncology Head

Novartis International AG /
Novartis appoints Elizabeth Barrett as Oncology Head
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.

* Novartis appoints experienced pharmaceuticals industry leader with strong
marketing skills to drive oncology business further

* Novartis appoints ad interim leader for its Global Drug Development
organization

Basel, January 11, 2018 - Novartis announced today that Elizabeth (Liz) Barrett,
currently Global President Oncology at Pfizer, Inc., has been appointed CEO
Novartis Oncology and a member of the Executive Committee of Novartis, effective
February 1, 2018. She will be based in Basel. Mrs. Barrett succeeds Bruno
Strigini who decided to retire from Novartis for personal reasons.

Vasant (Vas) Narasimhan, designated CEO of Novartis, said: "Liz is a highly
accomplished and recognized oncology and people leader with an impressive record
of building successful business organizations in the US, Europe and globally.
She has been instrumental in creating new commercial models, driving innovation
in close partnership with research and development and leveraging business
development opportunities. Her long-time commercial pharma industry experience,
marketing skills and perspectives make Liz a great fit to further develop our
oncology business."

Mrs. Barrett said: "I feel honored to join Novartis, a recognized pioneer in the
oncology area. It is key to me to contribute to transformative advancements in
oncology, and to serve in a highly impactful leadership role to this end."

Mrs. Barrett has held numerous leadership positions in the pharmaceutical
industry as well as in the consumer sector. In her most recent role at Pfizer,
she led the oncology business through a significant period of growth achieved in
less than three years. Before joining Pfizer in 2009, she worked at Cephalon,
Inc. and Johnson & Johnson. She started her career at Kraft Foods Group, Inc. in
1984.

Mrs. Barrett is a US citizen and has lived and worked in the US and Europe. She
obtained an MBA in Marketing from the Saint Joseph's University in Philadelphia
and a BSc in Business Administration from the University of Louisiana.

Novartis also announced today that Robert Kowalski, Pharm.D., Head of Global
Regulatory Affairs, will assume ad interim leadership of the Drug Development
Organization, effective February 1, 2018. Dr. Kowalski has been Head of Global
Regulatory Affairs for Novartis since February 2016 and has played an important
leadership role in securing approvals for several breakthrough medicines
including our revolutionary CAR-T therapy Kymriah(TM). The definitive Head of
Global Drug Development will be announced in due course.

Disclaimer
This press release contains forward-looking statements within the meaning of the
United States Private Securities Litigation Reform Act of 1995, . Forward-
looking statements can generally be identified by words such as "effective,"
"will," "to further develop," or similar expressions, or by express or implied
discussions regarding potential future sales or earnings of the Novartis Group.
You should not place undue reliance on these statements. Such forward looking
statements are based on our current beliefs and expectations regarding future
events, and are subject to significant known and unknown risks and
uncertainties. Should one or more of these risks or uncertainties materialize,
or should underlying assumptions prove incorrect, actual results may vary
materially from those set forth in the forward looking statements. There can be
no guarantee that Novartis will be commercially successful in the future, or
achieve any particular financial results. In particular, our expectations could
be affected by, among other things: regulatory actions or delays or government
regulation generally; the potential that the strategic benefits, synergies or
opportunities expected from the significant reorganizations of recent years may
not be realized or may take longer to realize than expected; the uncertainties
inherent in the research and development of new healthcare products; our ability
to obtain or maintain proprietary intellectual property protection on key
products; safety, quality or manufacturing issues; global trends toward health
care cost containment, including government, payor and general public pricing
and reimbursement pressures; uncertainties regarding actual or potential legal
proceedings; and other risks and factors referred to in Novartis AG's current
Form 20-F on file with the US Securities and Exchange Commission. Novartis is
providing the information in this press release as of this date and does not
undertake any obligation to update any forward-looking statements contained in
this press release as a result of new information, future events or otherwise.

About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has
leading positions globally in each of these areas. In 2016, the Group achieved
net sales of USD 48.5 billion, while R&D throughout the Group amounted to
approximately USD 9.0 billion. Novartis Group companies employ approximately
121,000 full-time-equivalent associates. Novartis products are sold in
approximately 155 countries around the world. For more information, please visit
http://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at
http://twitter.com/novartis
For Novartis multimedia content, please visit www.novartis.com/news/media-
library
For questions about the site or required registration, please contact
media.relations@novartis.com

# # #

Novartis Media Relations
Central media line: +41 61 324 2200
E-mail: media.relations@novartis.com

Paul Barrett Markus Jaggi
Novartis Global Media Relations Novartis Media Relations Switzerland
+41 61 324 7999 (direct) +41 61 324 9577 (direct)
+41 79 797 8137 (mobile) +41 79 673 7433 (mobile)
paul.barrett@novartis.com markus.jaggi@novartis.com

Eric Althoff Satoshi Sugimoto
Novartis Global Media Relations      Novartis Media Relations Switzerland
+41 61 324 7999 (direct) +41 61 324 6129
+41 79 593 4202 (mobile) +41 79 619 2035
eric.althoff@novartis.com satoshi_jean.sugimoto@novartis.com

Antonio Ligi
Novartis Global Media Relations
+41 61 324 1374 (direct)
+41 79 723 3681 (mobile)
antonio.ligi@novartis.com




Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com

Central   North America

Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448

Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 212 830 2417

Thomas Hungerbuehler +41 61 324 8425

Isabella Zinck +41 61 324 7188



Media release (PDF):
http://hugin.info/134323/R/2160737/831015.pdf



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novartis International AG via GlobeNewswire



 
 ||| Themen-Infos 
· Mehr zu dem Thema Allgemeine Nachrichten

Der meistgelesene Artikel zu dem Thema Allgemeine Nachrichten:
FDA expands age indication for Menveo®, first and only quadrivalent meningococcal vaccine for infants as young as 2 months of age[1]

 ||| Artikel Bewertung 
durchschnittliche Punktzahl: 0
Stimmen: 0

Bitte nehmen Sie sich einen Augenblick Zeit, diesen Artikel zu bewerten:

Exzellent
Sehr gut
gut
normal
schlecht



Web site engine's code is Copyright © 2003 by PHP-Nuke. All Rights Reserved. PHP-Nuke is Free Software released under the GNU/GPL license.
Erstellung der Seite: 0.085 Sekunden